Is Belzutifan an immune drug or a targeted drug? Drug Classification and Treatment Mechanism

Belzutifan (Belzutifan) is a targeted drug rather than an immunotherapy drug in the traditional sense. It is mainly an inhibitor of hypoxia-inducible factor -2α (HIF-2α), which intervenes in the growth and metabolic processes of tumors by targeting key proteins in the HIF pathway. The drug was developed by Merck & Co., Inc. in the United States and was initially approved by the FDA for the treatment of solid tumors such as renal cell carcinoma related to VHL (von Hipper- Lindau) disease.

In tumor cells, HIF-2α is a key factor that promotes cancer cell survival, proliferation and angiogenesis in a hypoxic environment. Under normal circumstances, HIF-2α will be degraded in an aerobic environment, but in some tumors (especially tumors related to VHL gene mutations) HIF-2α continues to be expressed, promoting malignant progression. Bestifan achieves anti-tumor effects by selectively inhibiting the activity of HIF-2α, blocking its formation of heterodimers with HIF-1β, and inhibiting the transcription of downstream cancer-promoting genes.

Unlike immunotherapy drugs (such as PD-1 and CTLA-4 antibodies) which rely on activating the patient's own immune system, Bestivan does not directly act on the immune pathway, but intervenes by targeting molecular abnormalities within the tumor. Therefore, it is clearly classified as a molecular targeted therapy drug in drug classification, rather than immune checkpoint inhibitors or cellular immunotherapy.

Currently, bezotivan is mainly used to treat kidney cancer, clear cell renal cell carcinoma and some neuroendocrine tumors related to VHL disease, and is undergoing clinical research in a number of solid tumor indications. With targetingHIFThe new idea of u200bu200bu200bu200bthe pathway is gradually recognized, and bezotivan provides a new treatment option for some tumor patients with clear targets but poor immunotherapy effects.

Reference materials:https://www.welireg.com/